Rheonix has named Frank Gill as its vice president of manufacturing. Gill will oversee manufacturing of Rheonix instrument platforms, reagent kits, and the Rheonix CARD system, the firm said.
Most recently, Gill was director, reagent manufacturing operations at Roche 454 Life Sciences. He also held similar positions at Immunicon, now part of Veridex, and Songbird Hearing.
Illumina has elected Gerald Möller and David Walt to its board of directors for three-year terms, until its annual meeting of stockholders in 2016.
The firm has also elected Robert Epstein to its board for one year, until the annual meeting of stockholders in 2014.
Agendia has appointed Peter Schineller to be its chief commercial officer, a new position. Previously, Schineller was senior vice president and chief commercial officer at Alexza Pharmaceuticals, and senior VP and general manager at Ventana Medical Systems.
He also served as senior VP of sales, marketing, and commercial operations at Genoptix Medical Laboratories, and was a co-founder of Verus Pharmaceuticals.
Jon Kayyem will serve as senior vice president of R&D at GenMark Diagnostics, replacing Jorge Garces, who has resigned to pursue other opportunities.
Kayyem is currently chief scientific officer at GenMark, which he cofounded. He served as the company's president and CEO for a stint in 2010, before the positions were filled by current CEO Hany Massarany.
SQI Diagnostics said this week that it has promoted Andrew Morris to be its CEO and president, effective June 17.
The company also promoted Claude Ricks to chair its board of directors, replacing outgoing chairman Eric Schneider, who will continue to serve as a director on the board and on audit and special committees.
Morris has been SQI Diagnostics' chief financial officer since 2004. He previously served as vice president of mergers at Ernst and Young Corporate Finance.